<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> prevalance and its association with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, disorders of the hemostasis system, the course and activity of the disease have been studied in SLE patients </plain></SENT>
<SENT sid="1" pm="."><plain>10.5% of 457 SLE patients in central and western part of Ukraine had <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> which non-significantly depended on sex, age and disease duration but was tightly associated with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> appears as an independent risk factor for <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disorders</z:e> which does not depend on <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> and system inflammatory reaction but is firmly associated with the presence of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I levels, thrombocyte <z:hpo ids='HP_0000752'>hyperactivity</z:hpo>, antithrombin III and tissue plasminogen activator deficiency </plain></SENT>
</text></document>